Sunitinib in kidney cancer: 10 years of experience and development.

about

Sunitinib in kidney cancer: 10 years of experience and development.

Item

http://www.wikidata.org/entity/Q39038214

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Sunitinib in kidney cancer: 10 years of experience and development.

@en

Sunitinib in kidney cancer: 10 years of experience and development.

@nl

type

Item

label

Sunitinib in kidney cancer: 10 years of experience and development.

@en

Sunitinib in kidney cancer: 10 years of experience and development.

@nl

prefLabel

Sunitinib in kidney cancer: 10 years of experience and development.

@en

Sunitinib in kidney cancer: 10 years of experience and development.

@nl

P1476

Sunitinib in kidney cancer: 10 years of experience and development

@en

P2093

Arnaud Mejean

http://www.w3.org/2001/XMLSchema#string

Elise Nassif

http://www.w3.org/2001/XMLSchema#string

Laetitia Mauge

http://www.w3.org/2001/XMLSchema#string

Marc-Olivier Timsit

http://www.w3.org/2001/XMLSchema#string

Stéphane Oudard

http://www.w3.org/2001/XMLSchema#string

Virginie Verkarre

http://www.w3.org/2001/XMLSchema#string

P2860

Modes of resistance to anti-angiogenic therapy

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature.

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.

P304

129-142

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14737140.2017.1272415

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27967249

http://www.w3.org/2001/XMLSchema#string